Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells

International Immunology

Volumn 17, Issue 6, 2005, Pages 695-704

  Amacker, Mario ^a   Engler, Olivier ^b   Kammer, Andreas R ^a   Vadrucci, Sonia ^c   Oberholzer, David ^a   Cerny, Andreas ^d   Zurbriggen, Rinaldo ^a  

^a Pevion Biotech Ltd   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

CTL induction; Hepatitis C vaccine

Indexed keywords

ASPARTYLLEUCYLMETHIONYLGLYCYLTYROSYLISOLEUCYLPROLYLLEUCYLVALINE; CD8 ANTIGEN; CHIMERIC IMMUNOPOTENTIATING RECONSTITUTED INFLUENZA VIROSOME; CHIMERIC PROTEIN; CORE PROTEIN; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; PHOSPHOLIPID; UNCLASSIFIED DRUG; VIROSOME; VIROSOME VACCINE; VIRUS GLYCOPROTEIN; HLA A ANTIGEN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUSION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; DRUG MECHANISM; ENCAPSULATION; HEPATITIS C; HEPATITIS C VIRUS; IMMUNOGENICITY; INFLUENZA VIRUS; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOLIPOSOME; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; VIRUS CORE; ACTIVE IMMUNIZATION; ANIMAL; GENETICS; IMMUNIZATION; IMMUNOLOGY; MEMBRANE FUSION; T LYMPHOCYTE SUBPOPULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; EPITOPES, T-LYMPHOCYTE; HEPATITIS C, CHRONIC; HLA-A ANTIGENS; IMMUNIZATION; IMMUNOTHERAPY, ACTIVE; INFLUENZA VACCINES; LIPOSOMES; MEMBRANE FUSION; MICE; MICE, TRANSGENIC; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, VIROSOME; VIRAL CORE PROTEINS; VIROSOMES;

EID: 26444556522     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxh249     Document Type: Article

References (51)

1. Almeida, J. D., Edwards, D. C., Brand, C. M. and Heath, T. D. 1975. Formation of virosomes from influenza subunits and liposomes. Lancet 2:899.
2. Gluck, R., Mischler, R., Brantschen, S., Just, M., Althaus, B. and Cryz, S. J., Jr. 1992. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 90:2491.
3. Zurbriggen, R., Novak-Hofer, I., Seelig, A. and Gluck, R. 2000. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog. Lipid Res. 39:3.
4. Zurbriggen, R. 2003. Immunostimulating reconstituted influenza virosomes. Vaccine 21:921.
5. Abrosch, F., Gluck, R. and Herzog, C. 1998. Clinical and immunological studies with a new virosome-based hepatitis A vaccine. In Proceeding of 2nd European Congress on Tropical Medicine, Federation of European Societies for Tropical Medicine and international Health Liverpool.
6. Holzer, B. R., Hatz, C., Schmidt-Sissolak, D., Gluck, R., Althaus, B. and Egger, M. 1996. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: A randomized controlled trial. Vaccine 14:982.
7. Conne, P., Gauthey, L., Vernet, P. et al. 1997. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 15:1675.
8. Cryz, S. J., Que, J. U. and Gluck, R. 1996. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 14:1381.
9. Gluck, R. and Wegmann, A. 1998. "Virosomes," a new liposome-like vaccine delivery system. In Lasic, D. D. and Papahadjopoulos, D., eds, Medical Applications of Liposomes, p. 75. Elsevier, Amsterdam.
10. Wilson, I. A., Skehel, J. J. and Wiley, D. C. 1981. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289:366.
11. Klenk, H. D., Rott, R., Orlich, M. and Blodorn, J. 1975. Activation of influenza A viruses by trypsin treatment. Virology 68:426.
12. 2 amino-terminal fusion peptide but not the coiled coil region. J. Biol. Chem. 271:13417.
13. 2-terminal segment during influenza virus-induced membrane fusion. J. Biol. Chem. 267:20225.
14. Matlin, K. S., Reggio, H., Helenius, A. and Simons, K. 1981. Infectious entry pathway of influenza virus in a canine kidney cell line. J. Cell Biol. 91:601.
15. Widmann, C., Maryanski, J. L., Romero, P. and Corradin, G. 1991. Differential stability of antigenic MHC class I-restricted synthetic peptides. J. Immunol. 147:3745.
16. Vadrucci, S. 2002. Influenza Virus Hemagglutinin-mediated Membrane Fusion: Mechanistic Studies and Potential Applications. PhD Thesis. Federal Institute of Technology (ETH) Zürich, Zürich (http://e-collection.ethbib.ethz.ch/cgi-bin/ show.pl?type=diss&nr=14765).
17. Hunziker, I. P., Grabscheid, B., Zurbriggen, R., Gluck, R., Pichler, W. J. and Cerny, A. 2002. In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus. Int. Immunol. 14:615.
18. Zinkernagel, R. M., Callahan, G. N., Klein, J. and Dennert, G. 1978. Cytotoxic T cells learn specificity for self H-2 during differentiation in the thymus. Nature 271:251.
19. Keene, J. A. and Forman, J. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155:768.
20. Bennett, S. R., Carbone, F. R., Karamalis, F., Miller, J. F. and Heath, W. R. 1997. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med. 186:65.
21. Toes, R. E., Ossendorp, F., Offringa, R. and Melief, C. J. 1999. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189:753.
22. Arkema, A., Huckriede, A., Schoen, P., Wilschut, J. and Daemen, T. 2000. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine 18:1327.
23. Aichele, P., Brduscha-Riem, K., Zinkernagel, R. M., Hengartner, H. and Pircher, H. 1995. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182:261.
24. Liang, T. J., Rehermann, B., Seeff, L. B. and Hoofnagle, J. H. 2000. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132:296.
25. Manns, M. P., McHutchison, J. G., Gordon, S. C. et al. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958.
26. Fried, M. W., Shiffman, M. L., Reddy, K. R. et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975.
27. Chisari, F. V. 1997. Cytotoxic T cells and viral hepatitis. J. Clin. Invest. 99:1472.
28. Rehermann, B. and Chisari, F. V. 2000. Cell mediated immune response to the hepatitis C virus. Curr. Top. Microbiol. Immunol. 242:299.
29. Cooper, S., Erickson, A. L., Adams, E. J. et al. 1999. Analysis of a successful immune response against hepatitis C virus. Immunity 10:439.
30. Gruner, N. H., Gerlach, T. J., Jung, M. C. et al. 2000. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J. Infect. Dis. 181:1528.
31. Hitomi, Y., McDonnell, W. M., Killeen, A. A. and Askari, F. K. 1995. Sequence analysis of the hepatitis C virus (HCV) core gene suggests the core protein as an appropriate target for HCV vaccine strategies. J. Viral Hepat. 2:235.
32. Cerny, A., McHutchison, J. G., Pasquinelli, C. et al. 1995. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J. Clin. Invest. 95:521.
33. Moreno, R., Jiang, L., Moehle, K. et al. 2001. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem 2:838.
34. Monnard, P. A., Oberholzer, T. and Luisi, P. 1997. Entrapment of nucleic acids in liposomes. Biochim. Biophys. Acta 1329:39.
35. Pascolo, S., Bervas, N., Ure, J. M., Smith, A. G., Lemonnier, F. A. and Perarnau, B. 1997. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J. Exp. Med. 185:2043.
36. Gerhard, W. 1976. The analysis of the monoclonal immune response to influenza virus. II. The antigenicity of the viral hemagglutinin. J. Exp. Med. 144:985.
37. Skehel, J. J. and Schild, G. C. 1971. The polypeptide composition of influenza A viruses. Virology 44:396.
38. Böttcher, C. J. F., Van Gent, C. M. and Pries, C. 1961. A rapid and sensitive sub-micro phosphorus determination. Anal. Chim. Acta 24:203.
39. Ball, E. H. 1986. Quantitation of proteins by elution of Coomassie brilliant blue R from stained bands after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal. Biochem. 155:23.
40. Bron, R., Ortiz, A., Dijkstra, J., Stegmann, T. and Wilschut, J. 1993. Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes). Methods Enzymol. 220:313.
41. Struck, D. K., Hoekstra, D. and Pagano, R. E. 1981. Use of resonance energy transfer to monitor membrane fusion. Biochemistry 20:4093.
42. Loyter, A., Citovsky, V. and Blumenthal, R. 1988. The use of fluorescence dequenching measurements to follow viral membrane fusion events. Methods Biochem. Anal. 33:129.
43. Mastrobattista, E., Schoen, P., Wilschut, J., Crommelin, D. J. and Storm, G. 2001. Targeting influenza virosomes to ovarian carcinoma cells. FEBS Lett. 509:71.
44. Gluck, R. 1999. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine 17:1782.
45. Gunther-Ausborn, S., Praetor, A. and Stegmann, T. 1995. Inhibition of influenza-induced membrane fusion by lysophosphatidylcholine. J. Biol. Chem. 270:29279.
46. Shangguan, T., Alford, D. and Bentz, J. 1996. Influenza-virus-liposome lipid mixing is leaky and largely insensitive to the material properties of the target membrane. Biochemistry 35:4956.
47. Smit, J. M., Li, G., Schoen, P., Corver, J., Bittman, R., Lin, K. C. and Wilschut, J. 2002. Fusion of alphaviruses with liposomes is a non-leaky process. FEBS Lett. 521:62.
48. Waelti, E., Wegmann, N., Schwaninger, R. et al. 2002. Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Cancer Res. 62:437.
49. Hunziker, I. P., Zurbriggen, R., Glueck, R. et al. 2001. Perspectives: Towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol. 38:475.
50. Sarobe, P., Pendleton, C. D., Akatsuka, T. et al. 1998. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J. Clin. Invest. 102:1239.
51. Schumacher, R., Adamina, M., Zurbriggen, R. et al. 2004. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine 22:714.